Skip to main content

Advertisement

Table 5 Clinical studies in other cancer types

From: Combination of CTLA-4 and PD-1 blockers for treatment of cancer

Cancer type Patients Trial, ID Follow-up Outcomes Reference
Malignant pleural mesothelioma Previously treated Phase 2
NCT03048474
> 12 months ORR, 38%
Median PFS, 6.2 months
6-month PFS rate, 50%
Median OS, not reached
12-month OS rate, 64%
Grade 3-4 AEs, 38%
Disselhorst et al 2019
Malignant pleural mesothelioma Previously treated Phase 2
NCT02716272
> 16 months ORR, 28%
Median PFS, 5.6 months
12-month PFS rate, 23%
Median OS rate, 15.9 months
12-month OS rate, 58%
Grade 3-4 AEs, 26%
Scherpereel et al 2019
Unresectable Sarcoma Previously treated Phase 2
NCT02500797
> 12 months Confirmed response, 16%
Median PFS, 4.1 months
Median OS, 14.3 months
Grade 3-4 AEs, 14%
D’Angelo et al 2018
Esophagogastric cancer Previously treated Phase 1/2
NCT01928394
  Investigator assessed ORR, 24%
Median PFS, 1.4 months
12-month PFS rate, 17%
Median OS, 6.9 months
18-month OS rate, 28%
Grade 3-4 AEs, 35%
Janjigian et al 2018
Prostate cancer Previously treated, AR-V7 positive Phase 2
NCT02601014
≥ 1.9 months ORR, 25%
Median PFS,3.7 months
Median OS, 8.2 months
Grade 3-4 AEs, 46%
Boudadi et al 2018